2023 World Conference on Lung Cancer (Posters)-EP08.02. Dosimetric Contribution of LAD Artery Sparing RT Plan in Lung Cancer Patients Who Received Definitive RT

EP08.02. Dosimetric Contribution of LAD Artery Sparing RT Plan in Lung Cancer Patients Who Received Definitive RT - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the dosimetric contribution of LAD (left anterior descending) artery sparing in radiotherapy (RT) plans for lung cancer patients. The newly defined criterion of limiting the 15Gy area volume of the LAD to less than 10% was evaluated in patients who previously received RT without LAD optimization. Replanning was performed using the LAD-V1510% criterion, while preserving target coverage and other organ at risk (OAR) dose-limiting parameters. <br /><br />In the study, 37 patients who had received RT for non-small cell lung cancer (NSCLC) were reanalyzed. The mean age was 66 years, with 89% of the patients being male. The majority of the previous plans (84%) were performed with intensity modulated radiotherapy (IMRT). <br /><br />When evaluating the previous RT plans, the mean LAD-V15 of the patients was 49%. After replanning with LAD optimization, the mean LAD-V15 was reduced to 11%. In 57% of patients, the LAD-V15 could be reduced below 10%. <br /><br />The mean heart dose and LAD dose were also significantly reduced in the new plans compared to the previous plans. The results suggest that LAD optimization can effectively reduce LAD dose exposure while maintaining optimal target coverage and other OAR doses in lung cancer patients receiving RT. <br /><br />This study highlights the importance of considering LAD sparing in the optimization of RT plans for NSCLC patients, as it may help reduce the risk of major cardiac events associated with high LAD doses.

Asset Subtitle

Serap Akyürek

Meta Tag

Speaker Serap Akyürek

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

dosimetric contribution

LAD artery sparing

radiotherapy plans

lung cancer patients

LAD-V1510% criterion

target coverage

organ at risk

non-small cell lung cancer

intensity modulated radiotherapy

heart dose